• Skip to primary navigation
  • Skip to main content
DB-I Logo

DenseBreast-info, Inc.

Get Smart About Being Dense

HOME/USA

EUROPE

Español

  • Home
  • For Patients
    • Patients Home
    • Dense Breasts: 5 Facts You Should Know
    • Is My Mammogram Enough?
    • Screening Tests After a Mammogram (Table)
    • Let’s Talk About Dense Breasts, Video Series
    • Patient Questions and Answers
    • Patient Resources by Language
    • Print: Patient Fact Sheet
    • Print: Patient Brochure
  • For Providers
    • Providers Home
    • CME/CE: “Dense Breasts, Risk, and Supplemental Screening”
    • Flow Chart: Who Needs More Screening?
    • Health Care Provider FAQs
    • Risk Model Tutorial
    • Table: Mammography Guideline Comparison
    • Table: Dense Breast Screening Guidelines
    • Table: High/Increased-Risk Screening Guidelines
    • DBI Research
    • Patient Resources
  • Screening Technologies
    • Screening Technologies Home
    • For Patients: Screening Tests After a Mammogram (Table)
    • For Providers: Cancer Detection by Screening Method (Table)
    • 2D/3D Mammography
    • Mammography AI Screening Tools, Comparative Tables
    • Breast Ultrasound (Sonogram)
    • Breast MRI
    • Contrast-Enhanced Mammography (CEM)
    • Molecular Breast Imaging
    • DBI Research
  • Inform/Insurance Laws
    • Inform/Insurance Laws Home
    • Inform: Federal FDA Dense Breast Reporting
    • Insurance
      • State Law Insurance Map and Federal HRSA Guidelines
      • State Law Insurance Table
      • Federal Insurance Bill: Find It Early Act
  • Blog & Press
  • About Us
    • About Us Home
    • Our Mission
    • World Dense Breast Day
    • Our Team
    • DBI Research
    • Let’s Talk About Dense Breasts, Video Series
    • Patient Resources
    • Contact Us
    • Please Donate
  • Our Corporate and Health Group Supporters
/ Blog / Hawaii and Utah Add Bills + MASAI Trial
Hawaii and Utah Add Bills + MASAI Trial | Dense Breast Info

Hawaii and Utah Add Bills + MASAI Trial

February 10, 2026 by JoAnn Pushkin

New State Insurance Bills

Two new state bills for expanded coverage for breast imaging: Hawaii HB2366, Utah HB0468. For existing state insurance laws, see our MAP.

color coded map of the united states

MASAI Trial

A large, randomized, prospective, controlled, single-blinded non-inferiority trial including nearly 106,000 women in the Swedish breast cancer screening program was conducted to compare interval cancer rates between women screened with standard double reading versus Transpara AI-supported mammography to triage mammograms that should undergo double reading. The study included a mix of tomosynthesis and 2D mammography. Interval cancers were defined as primary breast cancers diagnosed between two screening rounds (typically every 1.5 – 2 years in average-risk women) or within 2 years after the last scheduled screening that were not detected at screening.

  • The interval cancer rate was lower among women who received AI-supported mammography compared to those who had standard double reading.1
  • This effect was consistent across age and breast density.
  • Sensitivity was higher in the AI-supported mammography group2 and specificities were equal among both groups.3

AI-supported mammography improved cancer detection, reduced interval cancer rates and reduced radiologist workload by decreasing the need for double reading.  In the United States, double reading is not routinely performed and isolated AI interpretation is not yet accepted: there are barriers to implementation. Further, AI is not generally covered by insurance so facilities in the USA may opt to charge patients an out-of-pocket fee when offering AI.

1 Interval cancer rates were 1.55/1000 (82/53043) (95% CI 1·23–1·92) and 1·76/1000 (93/52872) (95% CI 1·42–2·15) in the intervention and control groups respectively, with a non-inferior proportion ratio of 0·88 (95% CI 0·65–1·18; p=0·41).

2 Sensitivities were 80.5% (338/420) and 73.8% (262/355) in the AI-supported and standard double reading groups, respectively.

3 Specificity was 98.5% in both groups (51852/52623 in the AI supported group vs. 51752/52517 in the double reading group).

DenseBreast‑info, Inc. is an independent, nonprofit organization. DBI is not affiliated with or endorsed by other organizations unless expressly identified. If you have questions about DBI’s programs or partnerships, please contact us.

© Unpublished, DenseBreast-info, Inc. ALL RIGHTS RESERVED | 501(c)(3) Public Charity

  • Online Privacy Policy
  • Online Terms of Use & Disclaimers

This website is for informational purposes only and is not intended to be a substitute for medical advice from a physician or to create a standard of care for health care providers. In addition, information has been provided by independent third parties and may not represent the views of DenseBreast-info.org. Please check with a physician regarding your specific condition, if you have any questions, or need a diagnosis. If you are experiencing an urgent medical condition, call your local emergency services [e.g., 9-1-1 (in the USA) or 1-1-2 (in Europe)].